Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Celularity (CELU) Cash & Equivalents (2020 - 2025)

Historic Cash & Equivalents for Celularity (CELU) over the last 6 years, with Q3 2025 value amounting to $120000.0.

  • Celularity's Cash & Equivalents fell 977.44% to $120000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $120000.0, marking a year-over-year decrease of 977.44%. This contributed to the annual value of $738000.0 for FY2024, which is 22511.01% up from last year.
  • Per Celularity's latest filing, its Cash & Equivalents stood at $120000.0 for Q3 2025, which was down 977.44% from $863000.0 recorded in Q2 2025.
  • In the past 5 years, Celularity's Cash & Equivalents ranged from a high of $73.3 million in Q3 2021 and a low of $211.0 during Q2 2021
  • For the 5-year period, Celularity's Cash & Equivalents averaged around $14.2 million, with its median value being $863000.0 (2025).
  • As far as peak fluctuations go, Celularity's Cash & Equivalents tumbled by 9997.06% in 2021, and later skyrocketed by 1800748293.84% in 2022.
  • Celularity's Cash & Equivalents (Quarter) stood at $37.2 million in 2021, then tumbled by 62.5% to $14.0 million in 2022, then crashed by 98.37% to $227000.0 in 2023, then skyrocketed by 225.11% to $738000.0 in 2024, then plummeted by 83.74% to $120000.0 in 2025.
  • Its Cash & Equivalents was $120000.0 in Q3 2025, compared to $863000.0 in Q2 2025 and $293000.0 in Q1 2025.